Tifcemalimab
Product Specifications
UNSPSC Description
Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuation factor) monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab can be used in research of cancer[1].
Target Antigen
CD28
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tifcemalimab.html
Purity
95.00
Solubility
10 mM in DMSO
Smiles
[Tifcemalimab]
References & Citations
[1]Jun M, et, al. Phase I Study of the Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas. Blood (2022) 140 (Supplement 1): 3716–3717.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99961/Tifcemalimab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99961/Tifcemalimab-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS949747 Inquire
Recombinant Rabbit Phosphorylase b kinase regulatory subunit alpha, liver isoform (PHKA2), partial
Ask
View Details 
